MedTrace Logo

Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer

NCT00466986 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-10-12

No results posted yet for this study

Summary

The purpose of this study is to determine if the combination of Abraxane and Carboplatin together will improve the chances of controlling recurrent ovarian/fallopian tube/peritoneal cancer.

Conditions

Interventions

DRUG

Abraxane

Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Southeastern Gynecologic Oncology

    lead OTHER

Principal Investigators

  • Benidict B Benigno, MD · Southeastern Gynecologic Oncology

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-11-30
Primary Completion
2011-10-31
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00466986 on ClinicalTrials.gov